Pharmaceuticals

Piper Jaffray has upgraded Medicis Pharmaceutical (NYSE: MRX) from Neutral to Overweight and has raised the price target from $30 to $38.

Endo Pharma (NASDAQ: ENDP) reports its Q4 adjusted EPS at $1.06, beating the consensus of $0.96. ENDP reports its Q4 revenue at $511 million, versus the consensus of $482.76 million. ENDP shares gained 1.95% to $35.00 in pre-market trading. Read more from Benzinga's Company news.

Endo (NASDAQ: ENDP) now estimates 2011 revenues to be between $2.35 billion and $2.45 billion, reported (GAAP) diluted earnings per share to be between $2.43 and $2.53 and adjusted diluted earnings per share to be between $4.20 and $4.30.

Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the fourth quarter 2010. Total revenues during the fourth quarter of 2010 increased 31 percent to $511 million, compared with $391 million in the same quarter of 2009. Net income for the three months ended December 31, 2010...

Goldman Sachs says that it is only modestly tweaking its Par Pharmaceutical (NYSE: PRX) estimates “following the quarter despite the miss, assuming that higher spending will not repeat going forward with operating expenses falling broadly in line with management's 3-year guidance.” “Continued slow...

Piper Jaffray, which lowered its PT on shares of Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), is providing some color on the stock. “With yesterday's weakness in the wake of the FDA setback on Xifaxan in non-constipation irritable bowel syndrome (IBS), we believe SLXP shares are trading at an...

Piper Jaffray has lowered the price target on Salix Pharmaceuticals (NASDAQ: SLXP) from $60 to $39 and maintains its Overweight rating.

Analysts at Canaccord downgrade Labopharm Inc (NASDAQ: DDSS) from “buy” to “hold.” DDSS shares dipped 10.38% to close at $0.733 yesterday. More Analyst Ratings here

On CNBC's Fast Money, Karen Finerman said that Omnicare's (NYSE: OCR) conference call was pretty good, and she also said that she likes the new CEO. Omnicare, Inc. (OCR) gained 6.41% in the regular trading session, but it surrendered its gains in the after hours. Salix Pharmaceuticals, Ltd. (NASDAQ...

Shares of Forest Laboratories (NYSE: FRX) are lower on the session by 0.03%, currently trading at $31.99. The stock had been moving largely higher over the past two months, but recently sold off and is now trading between the 50-day and 200-day moving averages. Options traders are buying calls on...

Shire plc (NASDAQ: SHPGY) announces that its subsidiaries Shire LLC and Shire Development Inc. have received a new Paragraph IV Notice Letter from Watson Laboratories, Inc. in Fort Lauderdale, Florida advising of the filing of an Abbreviated New Drug Application for a generic version of all...

Salix Pharmaceuticals Ltd (NASDAQ: SLXP) dipped 24.25% to $31.40 in the pre-market session. SLXP expects the US Food and Drug Administration to seek more data for its Xifaxan drug. AXT Inc (NASDAQ: AXTI) fell 9.45% to $7.57 in the pre-market session. AXTI reported weaker-than-expected Q4 results...

Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three ended December 31, 2010. Adjusted diluted EPS of $0.45 for the quarter ended December 31, 2010 compared to $0.33 for the same prior year quarter, an increase of 36%; Total revenues of $1.43 billion for the quarter ended...

Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported results for the fourth quarter and full year ended December 31, 2010. For the fourth quarter ended December 31, 2010, the Company reported total revenues of $227 million and income from continuing operations of $17.6 million, or $0.48...

Below are the top mid-cap drug manufacturers-other stocks on the NYSE and the NASDAQ in terms of cash. Warner Chilcott plc (NASDAQ: WCRX) had $1.07 billion in total cash and $5.22 billion in total debt for the latest quarter. Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had $1.03 billion in...